SS
DNTH icon

Steve Schonfeld’s Dianthus Therapeutics DNTH Stock Holding History

Steve Schonfeld’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.22M Sell
43,322
-30,146
-41% -$2.63M 0.02% 710
2026
Q1 		$6.17M Sell
73,468
-109,151
-60% -$6.32M 0.04% 430
2025
Q4 		$7.53M Buy
182,619
+54,366
+42% +$2.11M 0.03% 430
2025
Q3 		$5.05M Sell
128,253
-43,786
-25% -$1.12M 0.03% 587
2025
Q2 		$3.21M Buy
+172,039
New +$3.23M 0.02% 750
2018
Q3 		– Sell
-625
Closed -$135K – 843
2018
Q2 		$135K Buy
+625
New +$141K 0.01% 718

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Steve Schonfeld's DNTH Position: Q2 2026 in Review

Steve Schonfeld reduced its Dianthus Therapeutics (DNTH) stake by 41% in Q2 2026, selling an estimated $2.63M and leaving 43,322 shares worth $4.22M. The position accounts for 0.02% of the portfolio, ranked #710.

Steve Schonfeld first reported a position in DNTH in Q2 2018 and has held it in 6 quarters since. The position peaked at $7.53M in Q4 2025. 267 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Steve Schonfeld held 43,322 shares of Dianthus Therapeutics worth $4.22M as of Q2 2026.
  • Steve Schonfeld sold 30,146 Dianthus Therapeutics shares in Q2 2026, an estimated $2.63M.
  • Dianthus Therapeutics made up 0.02% of Steve Schonfeld's portfolio in Q2 2026, its #710 holding.
  • Steve Schonfeld first reported a position in Dianthus Therapeutics in Q2 2018 and has held it in 6 quarters since.
  • Steve Schonfeld's Dianthus Therapeutics position peaked at $7.53M in Q4 2025.
  • 267 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.